DLBCL
Feature
Widespread carboplatin, cisplatin shortages: NCCN survey
Only 64% of centers said they are still able to continue treating all current patients receiving carboplatin.
Conference Coverage
PMBCL: Postremission, patients may safely skip radiation
Among patients who had achieved complete remission of primary mediastinal B-cell lymphoma with chemotherapy, the largest study of its kind found...
Feature
DLBCL: Major new treatment breakthroughs
After decades of slow progress, new drugs and therapies are paving the way to more effective treatment of DLBCL.
From the Journals
Number of cancer survivors with functional limitations doubled in 20 years
The 70% prevalence of functional limitation among survivors in 2018 is nearly twice that of the general population.
From the Journals
Study shows higher obesity-related cancer mortality in areas with more fast food
An ecologic study showed a dose-response relationship among measures of food swamp and food desert scores and obesity-related cancer mortality.
Feature
Third-generation Black woman physician makes cancer research history
African American surgeon helped found ASCO and collaborated with her father to achieve lasting breakthroughs in chemotherapy.
Feature
Ex–hospital porter a neglected giant of cancer research
An Indian immigrant who once emptied bedpans in a Boston hospital went on to become the “father of chemotherapy.”
From the Journals
First-line CAR T-cell therapy could help cure some lymphomas
Axi-cel is already approved for some forms of relapsed/refractory lymphoma, and a new phase 2 study hints that it has potential as a frontline...
Feature
Repurposed drug could revolutionize stem cell transplantation
Abatacept to prevent for acute graft-versus-host disease is a game changer for patients receiving hematopoietic stem cell transplants who lack...
Latest News
EMA gives green light to new CAR T-cell therapy
The committee also recommended approval of a biosimilar product for pegfilgrastim.
Latest News
Yescarta label updated: Prophylactic steroids to prevent CRS
New Yescarta labeling advises clinicians to consider using corticosteroids to ward off cytokine release syndrome.